The relationship with carnitine pharmacokinetics and fatigue after cisplatine administration in cancer patients

The relationship with carnitine pharmacokinetics and fatigue after cisplatine administration in cancer patients - The relationship with carnitine pharmacokinetics and fatigue after cisplatine administration in cancer patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011596

Enrollment

Registered

2013-09-09

Start date

2013-09-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer patients of admission in scheduled chemotherapy including cisplatine (The target will be all type of tumor)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Cancer patients of admission in scheduled chemotherapy including cisplatine 2)PS(ECOG)0-1 3)Patients who agree with the documents 4)Patient ages at the point of agreement is less than 75 years old

Exclusion criteria

Exclusion criteria: 1)Patients of prognosis is less than 3 months 2)Hemoglobin < 10g/dL 3)Less than one month after operation or radiotherapy 4)Judgment of ineligible by physician excluding the above

Design outcomes

Primary

Measure	Time frame
Carnitine concentrations in plasma and urine Fatigue scale (FACIT-F)	—

Countries

Japan

Contacts

Public ContactTatsuhiko Kashii

Toyama university hospital Department of medical oncology

tkashii@med.u-toyama.ac.jp076-434-7808

Outcome results